Table 6.
Response assessment by TP53 mutation status in patients with MYD88WT
| Total (n = 20) | TP53WT (n = 16) | TP53MUT (n = 4) | |
|---|---|---|---|
| Best overall response, n (%) | |||
| CR | 1 (5.0) | 1 (6.3) | 0 (0.0) |
| VGPR | 3 (15.0) | 3 (18.8) | 0 (0.0) |
| PR | 8 (40.0) | 6 (37.5) | 2 (50.0) |
| MR | 4 (20.0) | 3 (18.8) | 1 (25.0) |
| SD | 3 (15.0) | 2 (12.5) | 1 (25.0) |
| PD | 1 (5.0) | 1 (6.3) | 0 (0.0) |
| VGPR or better, n (%) | 4 (20.0) | 4 (25.0) | 0 (0.0) |
| Major response, n (%) | 12 (60.0) | 10 (62.5) | 2 (50.0) |
| Time to response, median (min, max), mo | |||
| VGPR or CR | 9.6 (2.8, 22.1) | 9.6 (2.8, 22.1) | - |
| Major response | 3.4 (1.8, 44.6) | 3.3 (1.8, 44.6) | 4.3 (3.0, 5.5) |
Among 20 patients with MYD88WT, 4 patients with TP53MUT had a lower major response rate (50%), and none achieved VGPR or CR, compared with TP53WT patients.
max, maximum; min, minimum; MR, minor response; PD, progressive disease, SD, stable disease.